Assessment of dyslipidemia and atherogenic index of plasma in stage 3 to Stage 5 chronic kidney disease
Keywords:
atherogenic index, chronic Kidney disease, dyslipidemia and MDRDAbstract
In Chronic Kidney Disease leading factor for morbidity and mortality is Cardiovascular disease. In CKD there is a risk of cardiovascular complications more than 50%. Dyslipidemia is one of leading risk cause for cardiovascular complication in normal healthy individual and also in chronic kidney disease. The Study contains 180 in which 45 as control group and 135 will be CKD individuals with stage 3 to stage 5 each stage consist of 45 each. In all the subjects Serum sample was estimated for blood urea, creatinine, triglycerides, cholesterol, and HDL-C by using fully automatic chemistry analyzer. VLDL, LDL and AIP was calculated. GFR was estimated by MDRD formula. Data was expressed by Mean ±SD. The mean value of triglycerides and VLDL in serum are raised in CKD stages 3 to stage 5 compared with control and it is shown statistically significant (p<0.001). The HDL-C mean value is decreased in CKD stages 3 to stage 5 when compared with control and it is shown statistically significant (p<0.0001). The mean value of serum total cholesterol and LDL-C is not significantly significant in CKD stages 3 to stage 5 compared with control.
Downloads
References
Gooneratne IK, Ranaweera AK, Liyanarachchi NP, Gunawardane N, Lanerolle RD. Epidemiology of chronic kidney disease in a Sri Lankan population. International journal of diabetes in developing countries. 2008 Apr;28(2):60. https://doi.org/10.4103/0973-3930.43101
King W MA, Edward L Greene, Leopold Raij. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J kidney Dis.1992; 6:505-513. https://doi.org/10.1016/s0272-6386(12)80827-4
Lidner A, Charra B, Sherrard D. Accelerated atherosclerosis in prolonged maintainance hemodialysis. N Engl J Med.1974; 290:697-701. https://doi.org/10.1056/nejm197403282901301
Tetsuo Shoji, Eiji Ishimura, Masaaki Inaba, Tsutomu Tabata, Yoshiki Nishizawa. Atherogenic Lipoproteins in End stage renal disease. Am J kidney dis.2001; 38:S30-33. https://doi.org/10.1053/ajkd.2001.27393
Purohit P, Sharma P. Atherogenic index: A potential cardiovascular risk marker in coexisting hypothyroidism and diabetes mellitus at diagnosis. Journal of Obesity and Metabolic Research 2016 ; 3 (1): 46. http://dx.doi.org/10.4103/2347-9906.184174
Dobiasova M, Frohlich J, Sedova M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566–571. https://doi.org/10.1194/jlr.p011668.
Deighan CJ, Caslake MJ, McConnell M, Boulton Jones JM, Packard CJ (2000) Related atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 35: 852–862. https://doi.org/10.1016/s0272-6386(00)70255-1
Dobiasova M, Frohlich J. Th-P15:53 Atherogenic index of plasma (AIP) is an effective predictor of cardiovascular risk. Atherosclerosis Supplements. Elsevier BV; 2006 Jan;7(3):504. http://dx.doi.org/10.1016/s1567-5688(06)82013-1
Levey AS. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Annals of Internal Medicine. American College of Physicians; 1999 Mar 16;130(6):461. http://dx.doi.org/10.7326/0003-4819-130-6-199903160-00002
Rapoport J, Aviram M, Chaimovitz C, Brook JG. Defective High-Density Lipoprotein Composition in Patients on Chronic Hemodialysis. New England Journal of Medicine. Massachusetts Medical Society; 1978 Dec 14;299(24):1326–9. http://dx.doi.org/10.1056/nejm197812142992402
Bagdade JD, Albers JJ. Plasma High-Density Lipoprotein Concentrations in Chronic-Hemodialysis and Renal-Transplant Patients. New England Journal of Medicine. Massachusetts Medical Society; 1977 Jun 23; 296 (25): 1436 – 9. http://dx.doi.org/10.1056/nejm197706232962504.
Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney International. Elsevier BV; 1996 Dec;50(6):1928–35. http://dx.doi.org/10.1038/ki.1996.515
Moberly J, Attman P-O, Samuelsson O, Johansson A-C, Knight-Gibson C, Alaupovic P. Apolipoprotein C-III, Hypertriglyceridemia and Triglyceride-Rich Lipoproteins in Uremia. Mineral and Electrolyte Metabolism. S. Karger AG; 1999;25(4-6):258–62. Available from: http://dx.doi.org/10.1159/000057457
Huttunen JK, Pasternack A, Vänttinen T, Ehnholm C, Nikkilä EA. Lipoprotein Metabolism in Patients with Chronic Uremia. Acta Medica Scandinavica. Wiley; 2009 Apr 24; 204 (1-6):211–8. http://dx.doi.org/10.1111/j.0954-6820.1978.tb08426.x.
Cheung AK, Parker CJ, Ren K, Iverius P-H. Increased lipase inhibition in uremia: Identification of pre-β-HDL as a major inhibitor in normal and uremic plasma. Kidney International. Elsevier BV; 1996 May;49(5):1360–71. http://dx.doi.org/10.1038/ki.1996.192
Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney International. Elsevier BV; 1990 Mar;37(3):854–8. http://dx.doi.org/10.1038/ki.1990.58
Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. American Journal of Physiology-Renal Physiology. American Physiological Society; 1997 Dec 1;273(6):F925–F930. http://dx.doi.org/10.1152/ajprenal.1997.273.6.f925
Appel G. Lipid abnormalities in renal disease. Kidney International. Elsevier BV; 1991 Jan;39(1):169–83. http://dx.doi.org/10.1038/ki.1991.22
Tsimihodimos V. Dyslipidemia Associated with Chronic Kidney Disease. The Open Cardiovascular Medicine Journal. Bentham Science Publishers Ltd.; 2011 Feb 24;5(1):41–8. http://dx.doi.org/10.2174/1874192401105010041
Kaysen GA. Dyslipidemia in chronic kidney disease: Causes and consequences. Kidney International. Elsevier BV; 2006 Dec;70:S55–S58. http://dx.doi.org/10.1038/sj.ki.5001979
Tsumura M, Kinouchi T, Ono S, Nakajima T, Komoda T. Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease. Clinica Chimica Acta. Elsevier BV; 2001 Dec;314(1-2):27–37. http://dx.doi.org/10.1016/s0009-8981(01)00681-7
Attman P O, Alaupovic P. Lipid and Apolipoprotein Profiles of Uremic Dyslipoproteinemia -Relation to Renal Function and Dialysis. Nephron. S. Karger AG; 1991;57(4):401–10. http://dx.doi.org/10.1159/000186303
Liang K, Vaziri ND. Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure. Nephrology Dialysis Transplantation. Oxford University Press (OUP); 1997 Jul 1;12(7):1381–6. http://dx.doi.org/10.1093/ndt/12.7.1381
Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, et al. Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. Ovid Technologies (Wolters Kluwer Health); 2005 Dec;25(12):2615–22. http://dx.doi.org/10.1161/01.atv.0000188555.60475.c2
Okeleke VO. A Comparative Study of Lipid Profile in Chronic Renal Failure Patients on Dialysis. Academia Journal of Medicine. College of Medicine and Health Science, DireDawa University; 2018 Jun 27;1(1). http://dx.doi.org/10.21276/ajm.2018.1.1.3
Mordasini R, Frey F, Flury W, Klose G, Greten H. Selective Deficiency of Hepatic Triglyceride Lipase in Uremic Patients. New England Journal of Medicine. 1977 Dec 22; 297(25):1362–6. http://dx.doi.org/10.1056/nejm197712222972502
Vaziri N. Hepatic HDL receptor, SR-B1 and Apo A-I expression renal failure. Nephrology Dialysis Transplantation. Oxford University Press (OUP); 1999 Jun 1;14(6):1462–6. http://dx.doi.org/10.1093/ndt/14.6.1462
Guarnieri GF, Moracchiello M, Campanacci L, Ursini F, Ferri L, Valente M, et al. Lecithin-Cholesterol Acyltransferase (LCAT) Activity in Chronic Uremic Patients. Enzymes in Health and Disease. S. Karger AG; 179–85. http://dx.doi.org/10.1159/000401738
Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney International. Elsevier BV; 2003 Nov;64(5):1829–37. http://dx.doi.org/10.1046/j.1523-1755.2003.00285.x
Dobiášová M, Frohlich JJ. Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport. Clinica Chimica Acta. Elsevier BV; 1999 Aug;286(1-2):257–71. http://dx.doi.org/10.1016/s0009-8981(99)00106-0
Frohlich J, Dobiášová M. Fractional Esterification Rate of Cholesterol and Ratio of Triglycerides to HDL-Cholesterol Are Powerful Predictors of Positive Findings on Coronary Angiography. Clinical Chemistry. Oxford University Press (OUP); 2003 Nov 1;49(11):1873–80. http://dx.doi.org/10.1373/clinchem.2003.022558
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
